Vol. 19/No. 7

The burden on oncologists is becoming unmanageable, leading many practices to turn to advanced practice providers.

Srdan Verstovsek, MD, PhD, discusses the rationale for targeting JAK signaling, new drugs under study for this pathway, and clinical challenges associated with these therapies.

Zev A. Wainberg, MD, discusses data from the pancreatic cancer cohort of a trial evaluating cabiralizumab in combination with nivolumab.

Despite advancements in treatment strategies for mantle cell lymphoma, patients experience diminishing responses from sequential lines of therapy as their disease progresses, sharpening the focus on developing new agents and combinations.

When investigators looked at roughly 150,000 cases of well-differentiated thyroid cancer using the SEER database of the National Cancer Institute, they knew that the use of radioactive iodine in conjunction with surgery and other treatments for thyroid cancer had increased dramatically over the years.

The shortage of doctors and other professionals to fill available positions in oncology practice is not news to practitioners—the American Society of Clinical Oncology has long chronicled the growing need for young oncologists to fill the ranks as senior ones retire or leave due to burnout.

A panel of experts discusses the role of BRCA1/2 mutation testing and how and when to incorporate PARP inhibitors into the care of patients with BRCA-positive TNBC.

A growing appreciation of the role of the tumor microenvironment in fostering the development of malignancies is prompting the pursuit of anticancer therapies that target components of this supportive niche as opposed to the tumor itself.

The impact of staggering increases in the cost of individual antineoplastic agents for patients and the overall healthcare system cannot be overstated, and there appears to be no realistic solution to the current dilemma that is acceptable to the parties involved in this ongoing debate.

A novel inhibitor that targets the AKT node in the PI3K pathway may offer a treatment option in cases of resistance to chemotherapy in 2 patient populations: triple-negative breast cancer or ER-positive/HER2-negative breast cancer with certain molecular aberrations.